Price$9.36+2.34 (+33.43%)
2026-03-042026-06-05
News · 26 weeks60-50%
2025-12-142026-06-07
Mix4290d
- SEC Filings15(36%)
- Other14(33%)
- Insider10(24%)
- Earnings2(5%)
- Analyst1(2%)
Latest news
25 items- INSIDERChief Financial Officer Levy Raphi sold $352,115 worth of Ordinary Shares (32,500 units at $10.83), decreasing direct ownership by 18% to 147,680 units (SEC Form 4)4 - Alpha Tau Medical Ltd. (0001871321) (Issuer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau and Tolmar Announce Strategic Collaboration to Bring Alpha DaRT® Therapy to U.S. Urological Cancer Patients- Joint partnership leverages Alpha Tau's highly potent, localized alpha-radiation technology and Tolmar's commercial leadership to transform the U.S. uro-oncology landscape - Collaboration elevates prostate cancer as a core strategic focus, backed by Tolmar's initial $15M manufacturing investment, $20M equity infusion at $11.99 per share (25% premium to 30-day VWAP), and up to $161.5M in clinical, regulatory and commercial milestones for the first indication - Agreement grants Tolmar exclusive U.S. commercialization rights for prostate cancer, with an option to expand into bladder cancer subject to additional payments - Alpha Tau to manufacture Alpha DaRT for Tolmar's commercialization,
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces Strong Overall Survival Results from Alpha DaRT® Pancreatic Cancer Studies Presented at 2026 ASCO Annual Meeting- Results reinforce the potential feasibility and safety of Alpha DaRT as a one-time, minimally invasive intratumoral treatment that fits naturally into the patient journey - - Pooled analysis of three prospective Phase I/II studies in locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC) demonstrates encouraging median overall survival (mOS) across chemotherapy-naive, second-line, and heavily pretreated patient populations - - Patients treated with Alpha DaRT after 1st line chemotherapy reached median overall survival (mOS) of 11.2 and 11.1 months in metastatic and locally advanced disease, respectively, from the date of trial enrollment, compared to ~4 - 6 months for met
- ANALYSTBarclays initiated coverage on Alpha Tau with a new price targetBarclays initiated coverage of Alpha Tau with a rating of Overweight and set a new price target of $15.00
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces First Quarter 2026 Financial Results and Provides Corporate Update- Groundbreaking interim results from U.S. REGAIN trial in recurrent glioblastoma demonstrate 100% local disease control, 67% complete response rate, and favorable safety profile - - Completion of patient enrollment in the U.S. pivotal ReSTART trial in recurrent cutaneous squamous cell carcinoma, the Company's first U.S. pivotal study - - Pooled data from two pancreatic cancer trials presented at Digestive Disease Week (DDW) 2026 demonstrated 100% local disease control and favorable safety, the first oral presentation of Alpha DaRT® pancreatic data at a premier international gastroenterology conference - - Abstracts accepted for presentation at the 2026 ASCO Annual Meeting and at th
- PRAlpha Tau to Participate in May Investor ConferencesJERUSALEM, May 18, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. ("Alpha Tau", or the "Company") (NASDAQ:DRTS, DRTSW)), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT®, today announced that CFO Raphi Levy will participate in the following investor conferences in May 2026. Event:H.C. Wainwright 4th Annual BioConnect Investor ConferenceFormat:Fireside Chat and 1x1 MeetingsDate:Tuesday, May 19, 2026Time:10:30 – 11:00AM ETLocation:New York, NY Event:Rothschild & Co Redburn Radiopharma Conference 2026Format:1x1 MeetingsDate:Wednesday, May 27, 2026Location:New York, NY Event:Lytham Partners Spring 2026 Investor ConferenceFormat:Presentation and 1x1 MeetingsDate:Thu
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces Groundbreaking Interim Results from its U.S. Alpha DaRT® Recurrent Glioblastoma Trial, with 100% Local Disease Control, 67% Complete Response Rate, and Favorable Safety Profile Observed - Conference Call Scheduled for 8:30am ET- Interim results from the first three brain cancer patients treated; two of whom demonstrated complete response, with total disappearance of all enhancing tumor lesions, per multiple MRI scans since treatment - - One associated grade 3 serious adverse event (SAE) was observed, since resolved - - According to the National Brain Tumor Society, glioblastoma is one of the most complex, deadly, and treatment-resistant cancers, with an estimated average survival rate of only 8 months - - Conference call with principal investigator to be held today, Monday, May 11, 2026, at 8:30am ET - JERUSALEM, May 11, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or t
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau to Host Conference Call to Discuss Interim Results from First Three Patients Treated for Recurrent GlioblastomaJERUSALEM, May 08, 2026 (GLOBE NEWSWIRE) -- Alpha Tau Medical Ltd. (NASDAQ:DRTS, DRTSW)) ("Alpha Tau", or the "Company"), the developer of the innovative alpha-radiation cancer therapy Alpha DaRT® today announced that it will host a conference call and webcast on Monday, May 11, 2026 at 8:30am ET to discuss interim clinical data from the first three patients treated in its U.S. trial of Alpha DaRT for patients with recurrent glioblastoma (GBM), also known as the REGAIN (Recurrent Glioblastoma Alpha-DaRT Intratumoral Therapy) trial. Conference Call and Webcast Details Date: Monday, May 11, 2026Time: 8:30am ETWeb Access: https://alpha-tau-interim-results-conference-call.open-exchange.net/
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Completes Patient Enrollment in its U.S. Pivotal Skin Cancer Study, Advancing Towards Goal of FDA Approval of Alpha DaRT® to Treat Recurrent Cutaneous Squamous Cell Carcinoma- First U.S. pivotal study for Alpha Tau to have completed enrollment, representing a critical milestone on the path towards potential FDA pre-market approval (PMA); Company has already initiated PMA modular application process - - Enrollment of all 88 patients completed in the ReSTART trial, a U.S. multicenter pivotal study evaluating Alpha DaRT® for the treatment of recurrent cutaneous squamous cell carcinoma (cSCC), for which the Alpha DaRT has received Breakthrough Device Designation from the FDA - - ReSTART pivotal study builds on a foundation of clinical data from skin cancer studies conducted in Israel, Italy, France and the U.S. - - cSCC is the second most common form of skin canc
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Successfully Treats First Pancreatic Cancer Patient in Italy with Alpha DaRT® at the University of Verona's Pancreas InstituteFirst patient ever treated with Alpha DaRT for pancreatic cancer in Italy, under a clinical study conducted at the world-renowned Pancreas Institute of the University of VeronaThe study is the first Alpha DaRT pancreatic cancer protocol worldwide to permit both endoscopic ultrasound (EUS)-guided and percutaneous delivery of Alpha DaRT sources, expanding the spectrum of access alternatives available to physicians including interventional radiologists, interventional oncologists, gastroenterologists, endoscopists and surgeonsThe successful treatment follows the first European patient treated in April 2026 in France's ongoing multicenter ACAPELLA trial, and joins the ongoing IMPACT multicenter
- PRAlpha Tau Announces Upcoming Podium Presentation at the AHNS 12th International Conference on Head and Neck Cancer Showcasing Study Results of Alpha DaRT® Head and Neck Cancer Combination with Pembrolizumab- Abstract from trial evaluating Alpha DaRT® in combination with pembrolizumab in elderly patients with locally advanced and metastatic head and neck squamous cell carcinoma selected for podium presentation - - The AHNS International Conference on Head and Neck Cancer is widely recognized as one of the premier global forums dedicated to advancing head and neck oncology - - Clinical trial builds on Alpha DaRT monotherapy data generated across clinical studies in the United States, Europe, Israel, and Japan, and marks a key milestone in the Company's combination therapy strategy - - Head and neck cancer is the sixth most common malignancy worldwide, with elderly patients facing particularly
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- PRAlpha Tau Announces 100% Local Disease Control Rate and Favorable Safety Profile Observed in Alpha DaRT® Pancreatic Cancer Trials Presented at DDW 2026- 100% local disease control rate achieved in evaluable patients in pooled analysis of two first-in-human trials of Alpha DaRT® in pancreatic adenocarcinoma - - Favorable safety profile observed, with only 8 device-associated adverse events in 7 of 26 subjects (27%), nearly all resolving within two weeks in some of the most challenging, heavily pre-treated patients in oncology - - Highly heterogeneous patient population for whom available options are extremely limited included patients ineligible for chemotherapy as well as patients who had received up to four prior lines of chemotherapy - - Streamlined outpatient endoscopic ultrasound (EUS)-guided procedure designed for seamless integrat
- SECSEC Form 6-K filed by Alpha Tau Medical Ltd.6-K - Alpha Tau Medical Ltd. (0001871321) (Filer)
- SECSEC Form EFFECT filed by Alpha Tau Medical Ltd.EFFECT - Alpha Tau Medical Ltd. (0001871321) (Filer)
- SECSEC Form F-3 filed by Alpha Tau Medical Ltd.F-3 - Alpha Tau Medical Ltd. (0001871321) (Filer)
DRTS FAQ
6 questionsWhat does Alpha Tau Medical Ltd. do?
Alpha Tau Medical Ltd., a clinical-stage oncology therapeutics company, engages in research, development, and commercialization of diffusing alpha-emitters radiation therapy (Alpha DaRT) for the treatment of solid cancer In Israel and the United States. Its Alpha-DaRT technology used in clinical trials for skin, oral, pancreatic, and breast cancers; and preclinical studies for hepatic cell carcinoma, glioblastoma multiforme, lung cancer, and others. The company was incorporated in 2015 and is headquartered in Jerusalem, Israel.Where does DRTS stock trade?
Alpha Tau Medical Ltd. (DRTS) is listed on NASDAQ.What sector and industry is DRTS in?
Alpha Tau Medical Ltd. operates in the Health Care sector, Medical/Dental Instruments industry.What are analysts saying about DRTS?
Alpha Tau Medical Ltd. has had 7 recent analyst actions on file. The most recent action was from Barclays: Overweight with a $1500.00 price target on 2026-05-28. Recent price targets range from $500.00 to $2100.00.What companies are similar to DRTS?
Notable peers in the same industry include SYK (Stryker Corporation), MMM (3M Company), BSX (Boston Scientific Corporation), MDLN (Medline Inc.), BDX (Becton Dickinson and Company). Compare DRTS side-by-side with any of them on Quantisnow.How can I track DRTS on Quantisnow?
Quantisnow aggregates Alpha Tau Medical Ltd.'s SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow DRTS to receive live email and push alerts on every new disclosure.